Tenax Therapeutics Inc (TENX)

US · Healthcare · Biotechnology

$1.69+3.68%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Net profit

$-16.7M

EPS

$-0.31

EPS estimate

$-0.35

EPS came in at -0.31 against a street estimate of -0.35 — a beat of 11.4%.

Market cap

$61.0M

Forward P/E

0.3

P/B

0.60

Book value

$2.29

EPS (TTM)

$-1.39

52-week high

$19.40

52-week low

$1.31

50-day MA

$1.83

200-day MA

$9.85

Beta

0.97

Analysts rate Tenax Therapeutics Inc a buy (6 buy, 4 hold, 0 sell out of 10) with an average price target of $9.62.

Insiders

0.18%

Institutions

114.95%

Fund	Stake
FMR Inc	10.53%
Vivo Capital, LLC	6.68%
BlackRock Inc	4.62%
Perceptive Advisors LLC	4.54%
Vanguard Capital Management, LLC	3.07%
Millennium Management LLC	2.34%
Ikarian Capital, LLC	2.10%
Candriam Luxembourg S.C.A.	2.00%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tenax Therapeutics Inc — free to start.

Data updated 2026-11-07.